The MarketWatch News Department was not involved in the creation of this content. -- $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated ...

Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for ...

Atai Life Sciences announced a financing deal to raise approximately $50 million by selling 18,264,840 ordinary shares and pre-funded warrants to purchase an additional 4,566,210 shares. The funds ...

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today ...

Kiboko Gold Inc. (TSXV: KIB) (“Kiboko” or the “Company”) announces that, in connection with its non-brokered private placement announced on September 30, 2025 and amended on November 27, 2025 (the ...

Rule 144A and Regulation D offer exemptions from federal securities registration requirements under the Securities Act of 1933. However, they apply to different situations, and overseas companies must ...

The MarketWatch News Department was not involved in the creation of this content. $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA ...

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...